
|Videos|December 12, 2021
How to lower medical expenses for patients
Author(s)Urology Times staff
“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.
Advertisement
In this video, Kelvin A. Moses, MD, PhD, FACS, discusses the topics and advice from his presentation, “Financial and toxicity considerations when managing advanced PCa,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Moses is an associate professor of urology and fellowship director of urologic oncology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












